These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 6245621)
21. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients. Przybilla B; Burg G; Schmoeckel C; Braun-Falco O Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843 [TBL] [Abstract][Full Text] [Related]
22. [Current therapy concepts in cutaneous T-cell lymphomas]. Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537 [TBL] [Abstract][Full Text] [Related]
23. Antithymocyte globulin in the management of cutaneous T cell lymphoma. Edelson RL; Raafat J; Berger CL; Grossman M; Troyer C; Hardy M Cancer Treat Rep; 1979 Apr; 63(4):675-80. PubMed ID: 312698 [TBL] [Abstract][Full Text] [Related]
24. Exposure to chemicals, physical agents, and biologic agents in mycosis fungoides and the Sézary syndrome. Fischmann AB; Bunn PA; Guccion JG; Matthews MJ; Minna JD Cancer Treat Rep; 1979 Apr; 63(4):591-6. PubMed ID: 445514 [TBL] [Abstract][Full Text] [Related]
25. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides. Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425 [TBL] [Abstract][Full Text] [Related]
26. Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma. Funk A; Hensley F; Krempien R; Neuhof D; Van Kampen M; Treiber M; Roeder F; Timke C; Herfarth K; Helmbold P; Debus J; Bischof M Eur J Dermatol; 2008; 18(3):308-12. PubMed ID: 18474461 [TBL] [Abstract][Full Text] [Related]
27. [Sézary syndrome with ascitis: case report and review of the literature]. Nubourgh I; Van den Broeck K; Bradstreet C; Praet JP; Cantinieaux B Rev Med Brux; 2005; 26(5):445-50. PubMed ID: 16318098 [TBL] [Abstract][Full Text] [Related]
28. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas. Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809 [TBL] [Abstract][Full Text] [Related]
29. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Vidulich KA; Talpur R; Bassett RL; Duvic M Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011 [TBL] [Abstract][Full Text] [Related]
30. Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. Arvin AM; Pollard RB; Rasmussen LE; Merigan TC J Clin Invest; 1980 Apr; 65(4):869-78. PubMed ID: 6244336 [TBL] [Abstract][Full Text] [Related]
31. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer. Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053 [TBL] [Abstract][Full Text] [Related]
32. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541 [TBL] [Abstract][Full Text] [Related]
33. [Diagnosis and therapy of cutaneous T-cell lymphomas]. Le T; Pierard GE; Pierard-Franchimont C; de la Brassinne M; Lapière CM Dermatologica; 1984; 169(2):60-5. PubMed ID: 6332749 [TBL] [Abstract][Full Text] [Related]
34. [Reactivation of herpes zoster infection by varicella-zoster virus]. Cvjetković D; Jovanović J; Hrnjaković-Cvjetković I; Brkić S; Bogdanović M Med Pregl; 1999; 52(3-5):125-8. PubMed ID: 10518396 [TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Kim YH; Bishop K; Varghese A; Hoppe RT Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601 [TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus-negative Hodgkin's lymphoma after mycosis fungoides: molecular evidence for distinct clonal origin. Kremer M; Sandherr M; Geist B; Cabras AD; Höfler H; Fend F Mod Pathol; 2001 Feb; 14(2):91-7. PubMed ID: 11235910 [TBL] [Abstract][Full Text] [Related]
37. Mycosis fungoides associated with B-cell malignancies. Barzilai A; Trau H; David M; Feinmesser M; Bergman R; Shpiro D; Schiby G; Rosenblatt K; Or R; Hodak E Br J Dermatol; 2006 Aug; 155(2):379-86. PubMed ID: 16882178 [TBL] [Abstract][Full Text] [Related]
38. The spectrum of cutaneous lymphomas in Japan: a study of 62 cases based on the World Health Organization Classification. Yasukawa K; Kato N; Kodama K; Hamasaka A; Hata H J Cutan Pathol; 2006 Jul; 33(7):487-91. PubMed ID: 16872471 [TBL] [Abstract][Full Text] [Related]
39. Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides. Copur MS; Deshpande A; Mleczko K; Norvell M; Hrnicek GJ; Woodward S; Frankforter S; Mandolfo N; Fu K; Chan WC Croat Med J; 2005 Jun; 46(3):458-62. PubMed ID: 15861527 [TBL] [Abstract][Full Text] [Related]
40. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms. Dummer R; Foss F; Dreno B; Bagot M Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]